All In Biotech

Drug Trial Radar · NCT03989349

Efficacy & Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Aug 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 787 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

787

Actual

Start

Jun 30, 2019

Primary completion

Feb 23, 2022

Study completion Sep 26, 2022

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Jun 18, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of the study was to assess the efficacy and safety of nemolizumab after a 16-week treatment period in adult and adolescent subjects with moderate-to-severe atopic dermatitis (AD) not adequately controlled with topical treatments.

Conditions

  • Moderate-to-Severe Atopic Dermatitis

Interventions

  • PlaceboDrug

    Placebo

  • NemolizumabDrug

    Nemolizumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Intent-To-Treat (ITT) PopulationTime frame: Week 16
  2. Percentage of Participants With Investigator's Global Assessment (IGA) Success at Week 16: Severe Pruritus PopulationTime frame: Week 16
  3. Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: ITT PopulationTime frame: Week 16
  4. Percentage of Participants With >=75% Improvement in Eczema Area and Severity Index (EASI-75) at Week 16: Severe Pruritus PopulationTime frame: Week 16

Locations

138 sites in 11 countries. Site status is shown where the registry gives one.

  • Galderma Investigational Site 8749

    Birmingham, Alabama

  • Galderma Investigational Site 8893

    Birmingham, Alabama

  • Galderma Investigational Site 8866

    Guntersville, Alabama

  • Galderma Investigational Site 8808

    Scottsdale, Arizona

  • Galderma Investigational Site 8906

    Bell Gardens, California

  • Galderma Investigational Site 8905

    Canoga Park, California

  • Galderma Investigational Site 8577

    Encinitas, California

  • Galderma Investigational Site 8673

    Garden Grove, California

  • Galderma Investigational Site 8683

    Los Angeles, California

  • Galderma Investigational Site 8907

    Newport Beach, California

  • Galderma Investigational Site 8799

    Ontario, California

  • Galderma Investigational Site 8745

    Pasadena, California

  • Galderma Investigational Site 8658

    San Diego, California

  • Galderma Investigational Site 8536

    Santa Ana, California

  • Galderma Investigational Site 8820

    Westminster, California

  • Galderma Investigational Site 8637

    Farmington, Connecticut

  • Galderma Investigational Site 8875

    Delray Beach, Florida

  • Galderma Investigational Site 8391

    Hialeah, Florida

  • Galderma Investigational Site 8727

    Hialeah, Florida

  • Galderma Investigational Site 8523

    Largo, Florida

  • Galderma Investigational Site 8719

    Miami, Florida

  • Galderma Investigational Site 8656

    Miami, Florida

  • Galderma Investigational Site 8704

    Miami, Florida

  • Galderma Investigational Site 8706

    Miami, Florida

  • Galderma Investigational Site 8203

    Tampa, Florida

  • Galderma Investigational Site 8839

    Tampa, Florida

  • Galderma Investigational Site 8729

    Rolling Meadows, Illinois

  • Galderma Investigational Site 8724

    New Albany, Indiana

  • Galderma Investigational Site 8554

    Detroit, Michigan

  • Galderma Investigational Site 8825

    Las Vegas, Nevada

  • Galderma Investigational Site 8506

    Hackensack, New Jersey

  • Galderma Investigational Site 8741

    Buffalo, New York

  • Galderma Investigational Site 8723

    Cortland, New York

  • Galderma Investigational Site 8733

    New York, New York

  • Galderma Investigational Site 8823

    Greensboro, North Carolina

  • Galderma Investigational Site 8030

    Raleigh, North Carolina

  • Galderma Investigational Site 8747

    Cincinnati, Ohio

  • Galderma Investigational Site 8212

    Portland, Oregon

  • Galderma Investigational Site 8721

    Pittsburgh, Pennsylvania

  • Galderma Investigational Site 8713

    North Charleston, South Carolina

Showing 40 of 138 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.